{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:28:28Z","timestamp":1776508108395,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T00:00:00Z","timestamp":1418947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T00:00:00Z","timestamp":1418947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10637-014-0198-y","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T06:51:00Z","timestamp":1418971860000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Phase I study of the novel Cdc2\/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias"],"prefix":"10.1007","volume":"33","author":[{"given":"R.","family":"Tibes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. T.","family":"McDonagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Bogenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mohrland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Carpten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. T.","family":"Hagelstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"key":"198_CR1","doi-asserted-by":"crossref","unstructured":"Haferlach T (2008) Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program; 400\u2013411","DOI":"10.1182\/asheducation-2008.1.400"},{"key":"198_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.blre.2008.03.002","volume":"22","author":"CM Craig","year":"2008","unstructured":"Craig CM, Schiller GJ (2008) Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev 22:221\u2013234","journal-title":"Blood Rev"},{"key":"198_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.24862","volume":"116","author":"S Faderl","year":"2010","unstructured":"Faderl S, O'Brien S, Pui C-H et al (2010) Adult acute lymphoblastic leukemia. Cancer 116:1165\u20131176","journal-title":"Cancer"},{"key":"198_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/327031a0","volume":"327","author":"MG Lee","year":"1987","unstructured":"Lee MG, Nurse P (1987) Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327:31\u201335","journal-title":"Nature"},{"key":"198_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1385\/MB:32:3:227","volume":"32","author":"GR Stark","year":"2006","unstructured":"Stark GR, Taylor WR (2006) Control of the G2\/M transition. Mol Biotechnol 32:227\u2013248","journal-title":"Mol Biotechnol"},{"key":"198_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF02982021","volume":"75","author":"A Mori","year":"2002","unstructured":"Mori A, Wada H, Nishimura Y et al (2002) Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol 75:161\u2013165","journal-title":"Int J Hematol"},{"key":"198_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1365-2141.2000.02328.x","volume":"111","author":"C Adida","year":"2000","unstructured":"Adida C, Recher C, Raffoux E et al (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111:196\u2013203","journal-title":"Br J Haematol"},{"key":"198_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/10428190500052131","volume":"46","author":"JC Hernandez-Boluda","year":"2005","unstructured":"Hernandez-Boluda JC, Bellosillo B, Vela MC et al (2005) Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma 46:717\u2013722","journal-title":"Leuk Lymphoma"},{"key":"198_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2004.10.034","volume":"225","author":"E Conte","year":"2005","unstructured":"Conte E, Stagno F, Guglielmo P et al (2005) Survivin expression in chronic myeloid leukemia. Cancer Lett 225:105\u2013110","journal-title":"Cancer Lett"},{"key":"198_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2588.x","volume":"76","author":"R Invernizzi","year":"2006","unstructured":"Invernizzi R, Travaglino E, Benatti C et al (2006) Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol 76:494\u2013501","journal-title":"Eur J Haematol"},{"key":"198_CR11","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1080\/10428190412331283251","volume":"45","author":"R Invernizzi","year":"2004","unstructured":"Invernizzi R, Travaglino E, Lunghi M et al (2004) Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma 45:2229\u20132237","journal-title":"Leuk Lymphoma"},{"key":"198_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1532\/IJH97.A10408","volume":"80","author":"XL Cong","year":"2004","unstructured":"Cong XL, Han ZC (2004) Survivin and leukemia. Int J Hematol 80:232\u2013238","journal-title":"Int J Hematol"},{"key":"198_CR13","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-03-0642","volume":"10","author":"I Tamm","year":"2004","unstructured":"Tamm I, Richter S, Oltersdorf D et al (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10:3737\u20133744","journal-title":"Clin Cancer Res"},{"key":"198_CR14","doi-asserted-by":"crossref","unstructured":"Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD (2008) PI3K\/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol. 140(3):344--347","DOI":"10.1111\/j.1365-2141.2007.06920.x"},{"key":"198_CR15","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/leu.2011.46","volume":"25","author":"AM Martelli","year":"2011","unstructured":"Martelli AM, Evangelisti C, Chappell W et al (2011) Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway. Leukemia 25:1064\u20131079","journal-title":"Leukemia"},{"key":"198_CR16","first-page":"471","volume":"26","author":"FR Reis","year":"2011","unstructured":"Reis FR, Vasconcelos FC, Pereira DL et al (2011) Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep 26:471\u2013478","journal-title":"Oncol Rep"},{"key":"198_CR17","doi-asserted-by":"publisher","first-page":"13239","DOI":"10.1073\/pnas.0405407101","volume":"101","author":"C-C Chang","year":"2004","unstructured":"Chang C-C, Heller JD, Kuo J et al (2004) Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 101:13239\u201313244","journal-title":"Proc Natl Acad Sci U S A"},{"key":"198_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1080\/10428190601186143","volume":"48","author":"DH Mak","year":"2007","unstructured":"Mak DH, Schober WD, Chen W et al (2007) Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma 48:774\u2013785","journal-title":"Leuk Lymphoma"},{"key":"198_CR19","doi-asserted-by":"crossref","unstructured":"Goel S, Burris H, Mendelson D et al (2007) A phase I study of intravenous tetra-O-methyl nordihydroguaiaretic acid in patients with refractory malignancy. J Clin Investig; 25","DOI":"10.1200\/jco.2007.25.18_suppl.3584"},{"key":"198_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/neuonc\/nor230","volume":"14","author":"SA Grossman","year":"2012","unstructured":"Grossman SA, Ye X, Peereboom D et al (2012) Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 14:511\u2013517","journal-title":"Neuro Oncol"},{"key":"198_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","volume":"127","author":"CP Soupir","year":"2007","unstructured":"Soupir CP, Vergilio JA, Dal Cin P et al (2007) Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 127:642\u2013650","journal-title":"Am J Clin Pathol"},{"key":"198_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1532\/IJH97.04031","volume":"80","author":"K Sugahara","year":"2004","unstructured":"Sugahara K, Uemura A, Harasawa H et al (2004) Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol 80:52\u201358","journal-title":"Int J Hematol"},{"key":"198_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.leukres.2003.10.013","volume":"28","author":"Y Nakagawa","year":"2004","unstructured":"Nakagawa Y, Yamaguchi S, Hasegawa M et al (2004) Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 28:487\u2013494","journal-title":"Leuk Res"},{"key":"198_CR24","doi-asserted-by":"crossref","unstructured":"Tibes R, Giles F, McQueen T, et al (2006) Translational in vivo and in vitro studies in patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor. ASH Ann Meeting Abstracts; 108:1362","DOI":"10.1182\/blood.V108.11.1362.1362"},{"key":"198_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1126\/science.256.5055.382","volume":"256","author":"ET Kipreos","year":"1992","unstructured":"Kipreos ET, Wang JY (1992) Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 256:382\u2013385","journal-title":"Science"},{"key":"198_CR26","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D et al (2005) Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia 19:1774\u20131782","journal-title":"Leukemia"},{"key":"198_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.leu.2402824","volume":"17","author":"F Chang","year":"2003","unstructured":"Chang F, Lee JT, Navolanic PM et al (2003) Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590\u2013603","journal-title":"Leukemia"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0198-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0198-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:01:54Z","timestamp":1678510914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0198-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,19]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0198-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,19]]},"assertion":[{"value":"17 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}